Top Markets
#1 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +584.68%
#2 Phala Phala +79.72%
#3 Bitway Bitway +36.63%
#4 ARK ARK +34.99%
#5 龙虾 (Lobster) 龙虾 (Lobster) +27.51%
#6 Backpack Backpack +26.77%
#7 The Black Bull The Black Bull +24.78%
#8 Mubarak Mubarak +24.16%
#9 APEX APEX +22.33%
#10 B3 (Base) B3 (Base) +20.43%
Coin of the day
Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain)
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Ensysce Biosciences, Inc. Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.

ENSC
Classificação em ações #36735
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to... Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management. Another product, PF614-MPAR, is a combination of PF614 and nafamostat, in Phase I clinical development to provide overdose protection against excessive oral consumption. Furthermore, the company is exploring an oral and inhaled formulation of nafamostat for potential use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. The company's development efforts also include PF329, an extended-release hydromorphone prodrug similar to PF614. In the area of ADHD treatment, Ensysce is advancing PF8001 and PF8026, which are extended-release and immediate-release amphetamine prodrugs, respectively, aimed at deterring medication abuse. Additionally, PF26810, an extended-release methadone prodrug, is in development for opioid use disorder. Ensysce Biosciences, Inc. operates from its headquarters in La Jolla, California.
Preço da ação
$0.2483
Última sincronização: 2026-07-31
Valor de mercado
$2.30M
Variação (1 dia)
-3.39%
Variação (1 ano)
-89.01%
País
US
Negociar Ensysce Biosciences, Inc. (ENSC)

Categoria

Healthcare
Histórico de rendimento de dividendos para Ensysce Biosciences, Inc. (ENSC)
O rendimento de dividendos (TTM) da Ensysce Biosciences, Inc. (símbolo da ação: ENSC) em 2023-12-31 é: 0.00%
Rendimento médio dos dividendos nos últimos 5 anos: 11,707.83%
Histórico de rendimento de dividendos para Ensysce Biosciences, Inc. (ENSC) de 2017 a 2026
Rendimento de dividendos no final de cada ano (TTM)
Ano Rendimento de Dividendos Alterar
2026 (TTM) 0.00% -100.00%
2024 2,039.30% 0.00%
2023 0.00% -100.00%
2022 3.76% -99.99%
2021 56,496.11% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
2017 0.00% 0.00%
Rendimentos de dividendos (TTM) para empresas semelhantes ou concorrentes
Empresa Rendimento de Dividendos País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.36%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH